Breaking News

PCI Synthesis Passes Eighth FDA Inspection

November 16, 2011

Also passes sixth product PAI

PCI Synthesis, Inc. has successfully completed its eighth FDA inspection of its commercial manufacturing site in Newburyport, MA. The company has also received its sixth product pre-approval, which PCI’s partner expects to launch soon. PCI provides small and mid-sized companies with the development and manufacture of complex small molecules to be used as APIs.
 
“The latest successful FDA audit validates the ongoing investments we have made in our people, our cGMP systems, and our research, and to our continual process improvement. We have a smart team that understands the complex dynamics of small molecules, from making molecules, optimizing molecules, performing process improvements, and scaling up,” said Edward S. Price, president of PCI Synthesis. “Our focus and commitment to R&D is paying off, with our sixth product pre-approval, which assures the company of a steady stream of products in the years to come.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks